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ABSTRACT 
 
TRANSMISSIVE OLEFINATION OF ALKENENITRILES AND ALLYLIC HALIDES 
 
 
 
By 
Lihua Yao 
May, 2011 
 
Thesis supervised by Dr. Fraser Fleming 
 
Part 1. Grignard reagents readily add to alkenenitriles bearing an adjacent hydroxyl group 
to afford Z-alkenenitriles with transmissive relocation of the C=C bond. Mechanistically 
the transmissive olefination is consistent with rearrangement through a cyclic 6-
membered transition structure in which the formal displacement of hydroxide occurs by 
forming magnesium oxide.  
 
Part 2. Addition of niobium halides to a series of allylic or propargylic alkoxides directly 
provides allylic or allenic halides. Halogenation formally occurs through a metalla-halo-
[3, 3] rearrangement although at least these different mechanisms may operate 
competitively. Transposition of the olefin is equally effective for allylic alkoxides 
prepared by necleophilic addition, deprotonation, or reduction.  
 v 
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1. Introduction (Taken in part from the Journal of Medicinal Chemistry
1
) 
1.1 Background 
                                               
Over 30 nitrile-containing pharmaceuticals are prescribed for a diverse variety of 
medicinal indications with almost 20 nitrile-containing leads in clinical development. 
Trends identifying the roles of the nitrile in medical agents have emerged as the number 
of nitrile-containing pharmaceuticals has increased. Coupled with the increasing number 
of nitrile-containing agents have been structural advances that provide insight into the 
binding of small molecule inhibitors. X-ray crystallography in particular is providing key 
insight into small molecule-protein interactions through an increasing number of 
structures with inhibitors bound in the active site. Augmenting the available interactions 
with current nitrile-containing pharmaceuticals are details from clinical candidates no 
longer under development. 
 
The prevalence of nitrile-containing pharmaceuticals, and the continued stream of 
potential agents in the pipeline, attests to the biocompatibility of the nitrile functionality.
2
 
The nitrile group is not particularly electrophilic, even toward thiols such as glutathione,
3
 
unless activated by adjacent functionalities such as an electron withdrawing group.
4
 
Several new amino nitriles for diabetes treatment feature a reversible electrophilic attack, 
but involve a tightly orchestrated activation-electrophilic addition that is not otherwise 
readily achieved.  
 
The nitrile group is relatively robust and not readily metabolized.
5
 Metabolically, the 
nitrile group in most nitrile-containing pharmaceuticals is passed through the body 
 2 
unchanged.
6
 In cases of drug metabolism prior to elimination, the formation of 
glucuronides,
7
 conjugation with glutathione,
8
 N-dealkylation,
9
 N-acetylation,
10
 
hydrolysis, 
6a-d
 and oxidation
11
 typically occurs at sites remote from the nitrile and 
without modification of the nitrile group. 
 
Release of cyanide from aromatic or fully substituted carbons is not observed,
12
 whereas 
alkylnitriles bearing an adjacent proton can be oxidized in the liver to cyanohydrins with 
subsequent cyanide release.
13
 Mandelonitrile, a cyanohydrin produced by ingesting 
almonds or some fruit pits, releases cyanide as the main degradation pathway and is 
responsible for the toxicity of cyanogenic glycosides.
14
 The potential oxidation and 
cyanide ejection likely explains why only four of the bioactive nitriles in the review 
contain an adjacent C-H bond. Epoxidation of alkenenitriles and ring opening can 
potentially liberate cyanide, but the epoxidation is synthetically difficult
15
 and 
metabolism at other sites appears more likely given the success of several alkenenitrile-
containing pharmaceuticals. 
 
Vildagliptin 1 is a recently released aminonitrile-containing antidiabetic drug in which 
the nitrile bearing carbon is not fully substituted (Figure 1).
16
 Perhaps because of a 
concern for cyanide release, the metabolism has been closely examined in humans. The 
main metabolite comes from hydrolysis of the nitrile which likely stems from the 
covalent intermediate formed from this carboxyl transition structure analogue. Nitrile 
hydrolysis is rather rare and, when observed, is a very minor metabolic pathway.
17
 
 
 3 
 
Figure 1. Aminonitrile Vildagliptin 
 
Nitriles are unusual functionalities by virtue of the short, polarized triple bond.
18
 The 
linear, rodlike geometry has a cylindrical diameter of 3.6 Å for the π-system19 resulting in 
a minuscule steric demand along the axis. For comparison, the C≡N unit is essentially 8 
times smaller than a methyl group!
20
 Several crystal structures show the nitrile projecting 
into narrow clefts to make polar interactions or hydrogen bonds in sterically congested 
environments.
21
  
 
Nitriles often play a key role as hydrogen bond acceptors.
17, 22
 Several crystal structures 
show hydrogen bonding between the nitrile nitrogen and amino acids or to water which in 
turn is bound to the protein backbone. Many hydrogen bonds are between the nitrile and 
serine or arginine as expected for these hydrogen bond donors. In other clinical 
candidates, the strong dipole facilitates polar interactions in which the nitrile acts as a 
hydroxyl or carboxyl isostere. 
 
1.2 Alkenenitrile Pharmaceuticals 
 
Drugs containing the unsaturated nitrile functionality are conjugated either with 
additional electron withdrawing groups or heteroatoms (Figure 2).  Often the nitrile is 
 4 
positioned adjacent to a hydrogen bond donor or acceptor implying an electronic role for 
the nitrile group.  Conjugation of the nitrile with an additional electron withdrawing 
group facilitates Michael additions
23
 as in 2 (entacapone). 
 
2
24
 is a potent inhibitor of catechol-O-methyltransferase and used for treating Parkinson’s 
disease by facilitating passage of dopaminergic agents across the blood-brain barrier.
25
 
Molecular docking reveals a series of hydrogen bonds with the nitrocatechol ring but no 
specific interactions for the nitrile.
26
 3 (trilostane) is an inhibitor of 3β-hydroxysteroid 
dehydrogenase that was used to treat Cushing's syndrome in humans but is now licensed 
only for treating dogs.
27
 3 has been successfully used in treating post-menopausal women 
for breast cancer
28
 by inhibiting 3-hydroxysteroid dehydrogenase.
29
 Molecular modeling 
and mutant studies demonstrate the necessity of the nitrile group and identifies an 
interaction with a serine residue as being critical.
30
  
 
Figure 2. Alkenenitrile-Containing Pharmaceuticals 
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4 (lanoconazole)
31
 and 5 (luliconazole)
32
 are topical antifungal drugs developed and 
marketed in Japan. Both 4 and 5 inhibit sterol 14-methylase in fungi
31
 and although 
marketed as a racemate the activity resides in the S-enantiomer. An interaction is 
proposed between the enzyme and the dichlorobenzene ring
33
 with the dithioalkenenitrile 
acting as a Michael acceptor.
34
 6 (nilvadipine) is a calcium channel blocker used to treat 
hypertension and cerebral artery occlusion,
35
 and recently entered trials to treat 
Alzheimer's disease.
36
 The role of the nitrile is unknown.  
 
Celgene Corp.'s antitumor agent 7 (CC-5079) prevents tubulin polymerization but 
remains active against multi-drug resistant cells.
37
 Subsequent assays identified the Z-
diastereomer as being more active with molecular modeling suggesting a key hydrogen 
bond between the nitrile nitrogen and a tyrosine hydroxyl group in tubulin.
38
 8 
(levosimendan, Simdax) is a novel inodilator used to manage acute or chronic heart 
failure.
39
 As with many Ca
2+
 sensitization and K
+
 channel-mediators, the enzyme-
inhibitor interactions are not fully resolved. Development of a related dinitrile inhibitor, 9 
(KW-5092), suggests that the dinitrile creates a rigid, polar moiety comparable to a nitro 
group.
40
 
 
1.3 Conclusion 
 
Structurally diverse nitrile-containing drugs are in use for a variety of medical treatments. 
These range from blockbuster drugs to numerous candidates currently being pursued in 
clinical trials. Surveying the interactions of the nitrile within these pharmaceuticals and 
drug candidates reveals that the biological function of the nitrile group varies 
 6 
considerably. In some instances the nitrile merely polarizes the adjacent electron density 
whereas in other cases the nitrile is a key component for molecular recognition.  
 
Recent advances in molecular recognition, through crystallography, NMR, and modeling, 
is providing an increased understanding of the interactions between small molecule 
inhibitors and their targets. By surveying a range of pharmaceuticals and clinical 
candidates, several roles of the nitrile group have been identified.  
1.) Carbonyl bioisostere. In several non-steroidal inhibitors arylnitriles function as 
a carbonyl equivalent. These inhibitors have the advantage of minimizing 
interference with other steroid receptors and improving bioavailability. The 
homology is evident in the overlay of progesterone and the nitrile-inhibitor 10 
in the progesterone receptor site (Figure 3).
41
 The nitrile nitrogen occupies 
virtually the same position as the carbonyl oxygen of progesterone and engages 
in the same polar interactions. 
 
 
Figure 3. Nitrile Inhibitor 10 and Progesterone Overlay 
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2.) Hydroxyl and carboxyl surrogate. The small, polar nitrile is a strong hydrogen 
bond acceptor with a significant solvation shell. The combination allows the 
nitrile to function as hydroxyl and carboxyl surrogates. Hydrogen bonding is 
particularly common to the protein backbone, amino acid side chains, or water 
molecules enclosed within the binding domain. The relationship is exemplified 
by functional group replacements performed using the anti-cancer drug 13 
(etoposide) as a lead structure.
42
 Replacing the glycoside with a nitrile 11 was 
significantly more efficacious than the acid 12. 
 
 
Figure 4. Comparative Nitrile and Acid Etoposide Analogs. 
 
3.) Non–Specific Dipole Interaction. The powerful electron-withdrawing nature of 
the CN unit allows non-specific dipole interactions with amino acids and metal 
ions. In cyanoguanidines, and related structures, nitrile substitution allows 
tuning of the guanidine basicity and hydrogen bonding properties. 
4.) Azomethine-Water Bioisostere. Cyanoquinolines and cyanopyridines 15 can 
act as more potent azomethine-water 14 bioisosteres. Interchanging a water-
 8 
bound quinazoline with a 3-cyano quinoline or pyridine effectively exchanges 
the mobile hydrogen-bonded pyrimidine-water complex for a direct hydrogen 
bond between the nitrile and the protein. Expulsion of water from the binding 
domain adds an additional entropic component to the binding affinity (Figure 
5). 
 
Figure 5. Cyanoquinolines and Cyanopyridines as Azomethine-Water Bioisosteres 
 
5.) Carboxyl Transition State Analog. Several amino nitriles function as proline 
peptidases by reversibly forming covalently bound imino esters at the active 
site. Conversion of the nitrile to the imino ester appears choreographed through 
activation of the nitrile and addition of serine or cysteine. 
6.) Halogen Bioisostere. The nitrile mimics the polarization of the halides and is 
often an excellent halogen bioisostere.
43
 Being smaller than bromine or iodine, 
the nitrile is often capable of achieving better contact with amino acids lining 
an active site. 
7.) Improving ADME 44 -Toxicology Profiles. Computational properties and 
empirical rules such as Lipinski’s rules 45  are routinely employed to guide 
structure-based drug design.  While a potent molecule is essential for drug 
discovery, ultimately ADME-Tox properties decide which molecule is 
advanced into clinical trials. During optimization, leads tend to increase in size 
and lipophilicity
46
 which can be offset by introducing the sterically 
 9 
insignificant nitrile group.  Replacing a hydrogen with a nitrile can roughly 
lower cLogP
47
 by half an order of magnitude and nearly an order of magnitude 
reduction for LogD.
48
  A more dramatic decrease in lipophilicity by over a full 
order of magnitude for cLogP/LogD often occurs when replacing a halogen or 
methyl group by a nitrile. The development of 16 from 17 (capravirine) 
provides an excellent case study in modulating ADME properties through 
nitrile substitution. Refining 17 led to the truncated analog 17 that was 
evaluated and found to be less potent and more lipophilic.  Consistent with the 
nitrile being a halogen bioisostere, interchanging the chlorine with a nitrile (18 
→ 19) reduced the lipophilicity by an order of magnitude and increased the 
lipophilic-ligand efficiency (LLE).
49
 Introduction of a second nitrile led to 16 
with similar activity to 17, 141 mass units smaller, a decreased lipophilicity, 
and a much improved half-life in human liver microsomes (HLM); 7.5 minutes 
for 17 compared to 73 minutes for 16 (Figure 6). 
 
 10 
 
Figure 6. ADME-Directed Evolution of Capravirine 17 into Lersivirine 16. 
 
A comprehensive survey of the interactions between the nitrile group and a diverse range 
of bioactive receptors has been studied. Collating the nitrile-containing drugs and clinical 
candidates by their structural similarities, reveals at least seven different modes by which 
nitrile substituents accentuate binding to receptor targets. A greater understanding of 
these specific functions is likely to facilitate lead optimizations with nitrile-containing 
candidates and will, optimistically, increase the number of nitrile-containing 
pharmaceuticals. 
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2. Transmissive Olefination via Conjugate Addition-MgO Elimination (Taken in part 
from a manuscript in preparation for Angew Chem
50
) 
2.1 Introduction  
 
Six-membered transition structures are an essential motif in many powerful synthetic 
methods.
51
 [4+2] Cycloadditions, electrocyclic reactions, and [3,3]-sigmatropic 
rearrangements proceed through privileged six-electron, six-atom transition structures 
because the electron delocalization allows a low-energy pathway for the reaction. 
 
[3,3]-Sigmatropic rearrangements comprise a subset of six-electron reactions which 
generally favor rearrangement through a chair-like transition structure. [3,3]-Sigmatropic 
rearrangements exhibit a remarkable diversity of atom substitutions within the six-
membered ring (Figure 7). Cope, Claisen, and aza-Cope-Mannich reactions incorporate 
carbon, oxygen, and nitrogen ring atoms respectively. Related aldol, metal allylation, and 
intramolecular hydride reductions proceeding through Zimmerman-Traxler transition 
structures
52
 similarly proceed through 6 membered TS’s that incorporate a metal and a 
heteroatom.  
 
Figure 7. Generalized [3,3]-Sigmatropic Rearrangment. 
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The facility of these diverse, six-electron reactions hints at the possibility of new reaction 
modes. A conceptually intriguing variation of this six electron strategy is the anionic 
rearrangement driven by formation of a metal oxide (Scheme 1).
53
 Specifically, the 
addition of a Grignard reagent to a hydroxymethylacrylonitrile was anticipated to 
generate the alkylmagnesium alkoxide 24 whose [3,3]-sigmatropic rearrangement to the 
Z-alkenenitrile 25 would be aided by formation of magnesium oxide.
54
 Rearrangement 
through the chair transition structure 24b avoids the allylic strain present in 24a and 
would serve to efficiently favor the Z diastereomer.
55,56
 
 
Scheme 1. Transmissive Olefination Route to Alkenenitriles. 
Alkenenitriles are versatile synthetic intermediates
57
 that are readily transformed into an 
array of carbocycles
58
 and heterocycles.
[59]
 The alkenenitrile structural motif is also a key 
functionality embedded within several bioactive natural products
60
 and pharmaceuticals
61
 
which typically require selective access to one olefin geometry for bioactivity. The 
increasing isolation of alkenenitriles from natural sources,
62
 and their incorporation 
 13 
within drug targets underscores the need for rapid, modular stereoselective syntheses of 
alkenenitriles.
 63
  
 
2.2 Results and discussion 
 
The precursor hydroxy alkenenitriles are readily generated through ultrasound 
assisted
64
Bayliss-Hillman condensation.
65
 In a related strategy
66
, activation of the 
hydroxyl group, typically by acetylation, and allylic displacement affords α-substituted 
alkenenitriles.
 67 
 
Experimentally, the viability of initiating the magnesium oxide-driven rearrangement was 
explored through the addition of excess i-PrMgCl to hydroxynitrile 23a. Gratifyingly, the 
Z-alkenenitrile 25a was afforded in 56% yield (Table 1, entry 1) consistent with a 
concerted intramolecular rearrangement through the alkylmagnesium alkoxide 24. The 
addition-elimination requires three equivalents of Grignard reagent implying that the 
rearrangement proceeds via the more nucleophilic magnesiate 24b rather than an 
alkylmagnesium alkoxide.
68
 The incipient steric compression present in 24a is anticipated 
to favor rearrangement through 24b in which the small nitrile group is located in the 
more sterically demanding position. The extremely compact π-system of the nitrile resists 
nucleophilic attack by the proximal Grignard reagent, instead channeling the 
alkylmagnesium alkoxide to engage in a 6-electron transmissive olefination. Driven by 
the irreversible formation of magnesium oxide,
69
 the intramolecular rearrangement is 
remarkably facile and extremely selective
70 
for the Z-alkenenitrile 25a.
71
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Table 1. Transmissive Olefination of α-Hydroxy Alkenenitriles 
 
 
Entry Hydroxynitrile Grignard Alkenenitrile yield 
1 
 
i-PrMgCl 
 
56% 
2 
 
MeMgCl 
 
62% 
3 
 
BuMgCl 
 
77% 
4 
 
t-BuMgCl 
 
54% 
5 
 
Me3SiCH2MgCl 
 
52% 
6 
 
 
 
66% 
 15 
7 
 
BrMg
MeO
 
 
62% 
8 
 
 
i-PrMgCl 
 
 
60% 
 
9 
 
 
 
52% 
10 
 
 
 
63% 
11 
 
BuMgCl 
 
 
 
83% 
 
12 
 
BuMgCl 
 
68% 
13 
 
Me3SiCH2MgCl 
 
52% 
(6:1) 
 16 
14 
 
MeMgCl 
 
54% 
(4:1) 
15 
 
BuMgCl 
 
50% 
(6:1) 
 
The transmissive olefination is remarkably facile for an array of hydroxynitriles (Table 1). 
Aliphatic and olefinic Grignard reagents add with equal efficacy, with the skipped dienes 
25f, and 25i-j being generated without isomerization (Table 1, entry 6 and entries 9, 10). 
Addition of BuMgCl to nitrile 23a stereoselectively forms the perfumery agent 25c
72
 
(Table 1, entry 3). Modest oxygenation within the Grignard reagent is tolerated (Table 1, 
entry 7) although attempts to use the internally chelated, less nucleophilic 
bromomagnesium dioxolane were unsuccessful. Sterically demanding secondary (Table 1, 
entries 1 and 8) and tertiary Grignards (Table 1, entry 4) are as stereoselective as 
MeMgCl, the smallest nucleophilic Grignard reagent. The stereoselectivity is consistent 
with the size of the carbinol substituent determining the stereoselectivity rather than the 
alkyl group engaging in the transfer (Scheme 2). 
 
The utility of dienenitriles
73
 stimulated the transmissive olefination with the hydroxy 
dienenitrile 23d (Table 1, entries 13, 14 and 15). Addition of MeMgCl affords the 
dienenitrile 25n with a 4:1 preference for the Z stereochemistry whereas BuMgCl affords 
the dienenitrile 25o as a 6:1 Z:E mixture of diastereomers. Although the stereoselectivity 
is modest, this currently represents one of the most selective routes to this functionality. 
 
 17 
The transmissive olefination of hydroxy nitriles rapidly assembles Z-alkenenitriles from 
three readily available components: an aldehyde, acrylonitrile, and a Grignard reagent. 
The operational simplicity of the method stimulated applying the transmissive olefination 
to the synthesis of the neolignan morinol I.
 74
 Morinol I is one of a series of neolignans
75
 
that was isolated during a bioactivity guided isolation of extracts from the roots of the 
traditional Chinese medicinal herb Morina Chinensis. For such a relatively simple 
molecule, morinol I is rather remarkable. Morinol I is the only neoligan among the entire 
family of morinol metabolites to have a skipped diene. Other morinols are formally those 
having water added to the C7-C8 bond. Intriguingly, although Morinol I is drawn in the 
isolation report as having a skipped diene structure, the NMR data are more consistent 
with having a conjugated diene. Unfortunately a sample or spectral data is unavailable to 
resolve the structure of morinol I leaving synthesis as the most promising method for 
determining the correct structure of this metabolite. The structural assignment of the 
remaining family members appears secure, in part because morinol C and D have been 
synthesized.
76
 
 
Access to the putative structure of morinol I began with the ultrasound-promoted 
DABCO condensation
 
of veratraldehyde 24 with acrylonitrile (Scheme 2)
77
. Transmissive 
olefination of the resulting nitrile 23b initiated with vinylmagnesium bromide, readily 
installed the requisite Z-stereochemistry to afford the alkenenitrile 25p as a single 
stereoisomer. Mizoroki Heck addition of 3, 4-dimethoxyboronic acid to 25p selectively 
appended the second aromatic ring favoring the E-geometry by 8:1. Reduction of the 
nitrile to the corresponding alcohol via conventional i-Bu2AlH reduction
78
, hydrolysis, 
and aldehyde reduction was irreproducible and gave an aldehyde that was extremely 
 18 
prone to isomerization. Consequently an alternative reduction sequence was developed 
involving hydrolysis to amide, imide formation, and reduction (26→30). Using this 
sequence the putative morinol I was obtained without the formation of olefin isomers. 
Unfortunately alcohol 30 exhibits spectral data distinctly different for that reported from 
Morinol I. 
 
Scheme 2. Transmissive Olefination Route to 30 
 
Acess to the vinylsilane 25p provided a unique opportunity to prepare the Z-isomer of 
morinol I, a potential candidate for the natural product. Iodination of the vinylsilane 25i 
with NIS in hexafluroisopropanol
79
  provided the Z-vinyliodide 31 that was engaged in a 
Suzuki coupling to give 32 as a single isomer. Nitrile reduction via the hydrolysis, imide, 
and reduction sequence provided alcohol 35 again exhibiting spectral data different from 
that of morinol I
80
 (Scheme 3). 
 19 
 
Scheme 3. Transmissive Olefination Route to 35 
 
2.3 Conclusion 
 
The transmissive olefination of hydroxy alkenenitriles efficiently assembles Z-
alkenenitriles from three readily available components: an aldehyde, acrylonitrile, and a 
Grignard reagent. Adding excess Grignard reagent to an hydroxyl alkenenitrile triggers a 
6-electron transmissive olefination driven by formation of magnesium oxide. The 
versatility of the stereoselective Z-alkenenitrile synthesis is illustrated in a 5-step 
synthesis of several morinol lignans in an effort to determine the structure of the nature 
product. Collectively these syntheses establish the structure of morinol I as the only 
member of the morinol family having a conjugated diene. 
 
 
 
 20 
3. Allylic and Allenic Halide Synthesis via NbCl5- and NbBr5-Mediated Alkoxide 
Rearrangements (Taken in part from Journal of Organic Chemistry
81
) 
3.1 Introduction 
 
Allylic halides are powerful, versatile electrophiles.
82
 The excellent electrophilicity stems 
from stereoelectronic interactions between the σ*C-X orbital and the adjacent π system,
83
 
facilitating a range of efficient and predictable displacements.
84
 Numerous natural 
product syntheses have harnessed the excellent electrophilicity of allylic halides to 
overcome difficult displacements and challenging cyclizations.
85
  
Allylic halide intermediates in total synthesis campaigns are frequently synthesized from 
aldehydes through olefination-reduction-halogenation sequences (Scheme 4, 
36→37→38→39).86 The three-step sequence is necessitated in part because the requisite 
Wittig reagents suffer facile halide ejection,
87
 preventing a direct "halo-olefination," and 
partly because of the predictable conversion of primary allylic alcohols 38 to allylic 
halides 39 without rearrangement.
88
 In contrast, regioselective halogenation of secondary 
allylic alcohols is reagent
89
 and structure
90
 dependent with many reactions channeling 
through both SN2 and SN2' displacement manifolds.
91
  
 
Scheme 4. Typical Allylic Halide Synthesis 
 21 
Direct halogenation of propargylic alcohols similarly affords mixtures of regioisomeric 
halides.
91, 92  
Consequently a two steps sequence of alcohol activation, usually 
sulfonylation, followed by SN2' halide displacement is typically employed to convert 
propargylic alcohols 40 to terminal allenic halides 42 (Scheme 5, 40→41→42). 93 
Subsequent transition metal catalyzed coupling allows a diverse range of bond 
constructions on these valuable synthetic partners.
94
 
 
Scheme 5. Typical Allenic Halide Synthesis 
 
The inherent utility of allylic and allenic halides
95
 stimulated a direct
96
 synthesis from 
carbonyl and alcoholic precursors. Conceptually the transformation centers on a metalla-
halo-[3,3] rearrangement
97
 predicated on metal oxide elimination
98
 and the privileged 
nature of six-membered transition structures (Scheme 6).
99
 Addition of a vinyl metal 
bearing an appropriate halide was envisaged to access the allylic alkoxide 44 and trigger 
a concerted rearrangement to the corresponding allylic halide 45. As sporadically 
happens in chemical research,
100
 the same concept was being simultaneously pursued 
with allylic chlorotitanium alkoxides (44 MX=TiCl3).
101
 Mechanistic experiments with 
these titanium alkoxides implicated a stepwise ionization-halogenation sequence rather 
than a concerted rearrangement, although in principle tuning the metal oxophilicity and 
halogen nucleophilicity should favor a concerted halogen transfer.
102
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Scheme 6. Vinyl Addition-Metalla-Halo-[3,3]-Rearrangement 
 
Publication of the pioneering titanium-based allylic chloride synthesis was closely 
followed by communication
103
 of a complementary niobium pentahalide procedure. 
Although preliminary, the use of niobium broadened the substrate scope and offered the 
promise of a general approach to both allylic and allenic halides through a concerted 
rearrangement. Complete details of these niobium pentachloride and pentabromide 
rearrangements are provided with an emphasis on: mechanistic insight; extended 
substrate scope to include allylic alcohols, aldehydes, enals, ketones, and enones; cascade 
reduction-halogenation and addition-halogenation strategies; and the synthesis of allenic 
bromides. 
3.2 Results and discussion 
The metalla-halo-[3,3]-rearrangement strategy requires a metal halide capable of 
simultaneously activating the allylic alcohol, delivering a halogen in an SN2' 
displacement, and forming a stable metal oxide. 
The ability to chlorinate benzyl alcohol stimulated a direct nucleophilic addition-
chlorination with aldehydes (Scheme 7). Adding BuMgCl or BuLi to benzaldehyde 
affords metal alkoxides 46 that are readily transformed into the secondary benzylic 
chloride 47 upon exposure to NbCl5. An analogous addition of the chlorine-containing 
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Grignard reagent 48
104
 efficiently provides the dichloride 49 indicating that NbCl5 
tolerates additional chlorination in the substrate (Scheme 5). 
 
Scheme 7. Organometallic Addition-Chlorination with NbCl5 
 
The sequential addition-chlorinations with benzaldehyde (Scheme 8) provided an 
excellent foundation for the direct halo-olefination of aldehydes and ketones.
105
  In the 
optimized procedure, vinylmagnesium bromide
106
 was added to a THF solution
107
 of the 
aldehyde and then four volumes of dioxane and solid NbCl5 were added. After 10 min the 
crude chloride
108
 was isolated and subjected to phenylsulfenylate displacement in THF to 
afford, in the case of 3-methoxybenzaldehyde 43b, an excellent yield of the 
corresponding sulfide 51. 
 
Scheme 8. Direct Halo-Olefination-Sulfide Displacement of Aldehyde 
 
The niobium-mediated halogenation of metal alkoxides is equally effective for the 
addition of organometallics to unsaturated carbonyl compounds (Scheme 9). Reducing 
ketone 52 with LiBH4 and adding NbCl5 affords the corresponding chloride that was 
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displaced with sulfenate in an overall reductive-sulfenylation with translocation of the 
double bond. Collectively these addition-chlorination and reduction-chlorination 
sequences imply significant scope for halogenating allylic alkoxides generated as 
intermediates from different reactions. 
 
Scheme 9. Organometallic-Addition- NbCl5 Chlorination. 
The proclivity of allylic alcohols to participate in the formal metalla-halo-[3,3]-
rearrangement stimulated expanding the substrate scope to include propargylic alcohols 
(Table 2). Sequential deprotonation and chlorination of the propargylic alcohol 54a 
afforded only a trace of the allenyl chloride at room temperature, whereas coaxing the 
reaction with heating led to considerable decomposition. NbBr5 proved to be a more 
efficient halogenating agent triggering a smooth rearrangement at room temperature 
(Table 2, entry 1).  
The NbBr5 rearrangement is of reasonably broad scope and provides rapid access to 
synthetically versatile bromoallenes (Table 2).
109
 Secondary and tertiary propargylic 
alcohols react with similar efficiency (Table 2, entries 1-4, respectively). The 
bromination is equally applicable to alcohols with adjacent aromatic substitution as with 
aliphatic substituents (Table 2, compare entry 1 with entries 2-4). Although speculative, 
the allenyl bromide synthesis is envisaged through the hexacoordinate niobiate 55 formed 
 25 
through expansion of niobium's coordination sphere. Concomitant internal delivery of the 
halogen to the olefin terminus is likely promoted by forming trichloroniobium oxide.
110
 
 
Table 2. Metala-halo-[3, 3] rearrangement of Propargylic Alcohols 
 
entry propargyllic 
alcohol 
allenic bromide yield 
(%)
 
1 
      
 
53 
2 
  
 
62 
3 
 
   
 
 
65 
4 
  
 
57 
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3.3 Conclusion 
 
Allylic and allenic halides are readily generated by adding NbCl5 or NbBr5 to allylic or 
propargylic alkoxides. The halogenation formally occurs through a metalla-halo [3,3] 
rearrangement although ionization and direct displacement mechanisms appear to 
compete in some cases. The intermediate allylic alkoxides can be prepared by 
deprotonation or, equally as effectively, through an organometallic addition or reduction 
allowing the direct conversion of an aldehyde or ketone to the corresponding allylic 
chloride. Particularly useful is the direct "halo-olefination" of aromatic and aliphatic 
aldehydes by sequential addition of vinylmagnesium bromide and NbCl5 or NbBr5 which 
overcomes the current multi-step sequences. Secondary or tertiary propargylic alcohols 
react similarly with NbBr5 to afford allenylic bromides. The halides are readily isolated in 
pure form through simple extraction and can be used in subsequent displacements 
without prior purification.  
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 4. Experimentals 
General Procedure A for Baylis-Hillman Reaction: To a stirred solution of aldehyde (1 
mmol) and DABCO (1, 4-diazabicyclo[2,2,2]octane) (10 mmol) in a mixture solvent of 
1,4-dioxane (4 ml) and water (1 ml), was added acrylonitrile (10 mmol). The resulting 
clear mixture was stirred at room temperature for 48 h. Then 1N HCl was added to the 
mixture until an acidic mixture (PH = 6) is formed. After ethyl acetate (30 ml) was added, 
the organic phase was separated and the water phase was extracted with ethyl acetate 
(2×10 ml). The combined organic phase was washed with brine and dried over anhydrous 
magnesium sulfate. After removing of the solvent and low bolting-point substance, the 
crude product was purified by radial chromatography to afford analytically pure material. 
 
General Procedure B for Baylis-Hillman Reaction: To a stirred solution of aldehyde (1 
mmol) and DABCO (1,4-diazabicyclo[2,2,2]octane) (0.6 mmol) in a mixture solvent of 
1,4-dioxane (4 ml) and water (1 ml), was added acrylonitrile (2.0 mmol). The resulting 
clear mixture vibrates with ultrasonic at room temperature for 5h. Then 1N HCl was 
added to the mixture until an acidic mixture (PH = 6) is formed. After ethyl acetate (30 
ml) was added, the organic phase was separated and the water phase was extracted with 
ethyl acetate (2×10 ml). The combined organic phase was washed with brine and dried 
over anhydrous magnesium sulfate. After recrystallization, the crude product was purified 
to afford analytically pure material. 
 
General Procedure C for Transmissive Olefination via Conjugate Addition-MgO 
Elimination: To a stirred THF solution of 23 at a -20°C was added a Gringard reagent 
(3.0 equiv) slowly. After 3 h, the mixture was quenched with 0.1 M HCl solution, the 
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resulting mixture was stirred vigorously for 5 min. The crude product was extracted with 
ether, dried (MgSO4), concentrated, and purified by radial chromatography to afford 
analytically pure material.  
 
2-(Hydroxy-phenyl-methyl)-acrylonitrile (23a): General Procedure A for Baylis-
Hillman Reaction was employed with benzyl aldehyde (1.06 g, 10 mmol) to afford, after 
purification by radial chromatography (25% EtOAc in hexanes), 1.45 g (91%) of 23a as 
an oil: 
1
H NMR (CDCl3, 400 MHz): δ 3.36 (s, 1H), 5.22 (s, 1H), 5.98 (s, 1H), 6.05 (s, 
1H), 7.35 – 7.42 (m, 5H); 13C NMR (CDCl3, 100 MHz): δ 73.9; 116.9; 126.0; 126.4; 
128.8; 130.0; 139.0 ppm. 
 
2-[(3, 4-Dimethoxy-phenyl)-hydroxy-methyl]-acrylonitrile (23b): General Procedure 
B for Baylis-Hillman Reaction was employed with 3, 4-dimeoxy benzyl aldehyde (1.66 
g, 10 mmol) to afford, after purification by radial chromatography (35% EtOAc in 
hexanes),  2.06g (95%) of 23b as an oil: 
1
H NMR(CDCl3, 400 MHz): δ 3.78 (s, 1H), 3.81 
(s, 3H), 3.81 (s, 3H), 5.15 (s, 1H), 5.94 (s, 1H), 5.94 (s, 1H), 6.80 – 6.87 (m, 3H); 13C 
NMR (CDCl3, 100 MHz): δ 55.5, 73.2, 109.1, 110.8, 116.8, 118.8, 126.1, 129.4, 131.6, 
148.6, 148.7 ppm. 
 
2-((3,4-difluorophenyl)(hydroxy)methyl)acrylonitrile (23c): General Procedure A for 
Baylis-Hillman Reaction was employed with 3,4-difluorobenzaldehyde (1.42 g, 10 
mmol) to afford, after purification by radial chromatography (25% EtOAc in hexanes), 
1.46 g (75%) of 23c as an oil: IR (neat) 2231 cm
-1
; 
1
H NMR (CDCl3, 400 MHz): δ 3.98 
(s, 1H), 5.25 (s, 1H), 6.01 (s, 1H), 6.12 (s, 1H), 7.01 – 7.25 (m, 3H); 13C NMR (CDCl3, 
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100 MHz): δ 72.8, 115.5 (d, J = 18 Hz) , 116.7, 117.6 (d, J = 17 Hz) , 122.7 (d, J = 4 Hz), 
125.6, 131.1, 136.4 (d, J = 9 Hz) , 150.3 (d, J =  248 Hz) , 150.4 (d, J =  248 Hz) ppm. 
 
3-Hydroxy-2-methylene-5-phenyl-pent-4-enenitrile (23d): General Procedure A for 
Baylis-Hillman Reaction was employed with cinnamyl aldehyde (1.32 g, 10 mmol) to 
afford, after purification by radial chromatography (25% EtOAc in hexanes), 1.35 g 
(73%) of 23d as an oil: 
1
H NMR (CDCl3, 400 MHz): δ 3.59 (s, 1H), 4.84 (d, J = 7 Hz), 
5.93 (s, 3H), 6.02 (s, 3H), 6.14 (dd, J = 16 Hz, 7 Hz, 1H), 6.66 (d, J = 16 Hz, 1H), 7.24 – 
7.36 (m, 5H); 
13
C NMR (CDCl3, 100 MHz): δ 72.5, 116.9, 125.1, 126.4, 126.6, 128.2, 
128.5, 130.3, 133.3, 135.5 ppm. 
 
(Z)-2-Benzylidene-4-methyl-pentanenitrile (25a): General Procedure C was employed 
with 23a (40.0mg, 0.25mmol) and isopropyl magnesium bromide (0.43ml, 0.75mmol) to 
afford, after purification by radial chromatography (hexanes), 25.9 mg (56%) of 25a as 
an oil: IR (neat) 2209, 2957 cm
-1
; 
1
H NMR (CDCl3, 400 MHz): δ 0.99 (d, J = 6.8 HZ, 
6H), 2.00 – 2.06 (m, 1H), 2.27 (d, J = 7.3 HZ, 2H), 6.90 (s, 1H), 7.38 – 7.74 (m, 5H); 13C 
NMR (CDCl3, 100 MHz): δ 24.8, 30.4, 48.3, 113.5, 121.8, 131.4, 131.6, 132.7, 136.3, 
147.1 ppm; HRMS for  C13H15N: [M+Na
+
] calculated: 208.1102, found: 208.1093. 
 
(Z)-2-Benzylidene-butyronitrile (25b): General Procedure C was employed with 23a 
(40.0mg, 0.25mmol) and methyl magnesium bromide (0.33ml, 0.75mmol) to afford, after 
purification by radial chromatography (hexanes), 24.3 mg (62%) of 25b as an oil: IR 
(neat) 2972, 2209cm
-1
; 
1
H NMR (CDCl3, 400 MHz): δ 1.26 (t, J = 7.0 Hz, 3H), 2.45 (q, J 
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= 7.0 Hz, 2H), 6.94 (s, 1H), 7.38 – 7.43 (m, 3H), 7.70 – 7.73 (m, 2H); 13C NMR(CDCl3, 
100 MHz): δ 13.0, 29.6, 113.0, 118.7, 128.5, 128.8, 129.8, 133.8, 142.5 ppm. 
 
(Z)-2-Benzylidene-heptanenitrile (25c): General Procedure C was employed with 23a 
(40.0 mg, 0.25 mmol) and butyl magnesium chloride (0.43ml, 0.75mmol) to afford, after 
purification by radial chromatography (hexanes), 38.5 mg (77%) of 25c as an oil: IR 
(neat) 2928，2209 cm-1; 1H NMR(CDCl3, 400 MHz): δ 0.92 (t, J = 7.0 Hz, 3H), 1.33 – 
1.38 (m, 4H), 164 – 1.70 (m, 2H), 2.40 (t, J = 7.7 Hz, 2H), 6.92 (s, 1H), 7.39 – 7.42 (m, 
3H), 7.71 – 7.73 (m, 2H); 13C NMR (CDCl3, 100 MHz): δ 14.0, 22.3, 27.9, 30.8, 36.2, 
111.6, 118.8, 128.5, 128.8, 129.8, 133.8, 143.2 ppm. 
 
(Z)-2-Benzylidene-4,4-dimethyl-pentanenitrile (25d): General Procedure C was 
employed with 23a (40.0mg, 0.25mmol) and t-butyl magnesium chloride (0.75ml, 
0.75mmol) to afford, after purification by radial chromatography (hexanes), 27.0 mg 
(54%) of 25d as an oil: IR (neat) 2959, 2209 cm
-1
; 
1
H NMR (CDCl3, 400 MHz): δ 1.05 
(s, 9H), 2.30 (s, 2H), 6.88 (s, 1H), 7.39 - 7.75 (m, 5H); 
13
C NMR (CDCl3, 100 MHz): δ 
32.1, 35.4, 52.7, 111.5, 122.9, 131.5, 131.6, 132.8, 136.7, 149.3 ppm; HRMS C14H17N: 
[M+Na
+
] calculated:
 
222.1259, found: 222.1245. 
 
(Z)-2-Benzylidene-4-trimethylsilanyl-butyronitrile (25e): General Procedure C was 
employed with 23a (40.0 mg, 0.25mmol) and trimethylsilyl methyl magnesium chlroride 
(0.75 ml, 0.75mmol) to afford, after purification by radial chromatography (hexanes), 
31.6 mg (52%) of 25e as an oil: IR (neat) 2953, 2209 cm
-1
; 
1
H NMR (CDCl3, 400 MHz): 
δ 0.06 (s, 9H), 0.86 – 0.91 (m, 2H), 2.38 – 2.43 (m, 2H), 6.94 (s, 1H), 7.34 – 7.72 (m, 
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5H); 
13
C NMR (CDCl3, 100 MHz): δ -1.8, 15.7, 31.1, 114.4, 118.9, 128.5, 128.8, 129.7, 
133.9, 141.7 ppm; HRMS C14H19NSi: [M+Na
+
] calculated:
 
252.1185, found: 252.1191. 
 
(Z)-2-Benzylidene-pent-4-enenitrile (25f): General Procedure C was employed with 
23a (40.0mg, 0.25mmol) and vinyl magnesium bromide (1.1ml, 0.75mmol) to afford, 
after purification by radial chromatography (hexanes), 27.9mg (66%) of 25f as an oil: IR 
(neat) 2926, 2209，1641 cm-1; 1H NMR (CDCl3, 400 MHz): δ 3.11 (dd, J = 1.0HZ, 6.4 
HZ, 2H), 5.21 – 5.25 (m, 2H), 5.82 – 5.90 (m, 1H), 6.93 (s, 1H), 7.34 – 7.71 (m, 5H); 13C 
NMR (CDCl3, 100 MHz): δ 42.9, 112.3, 121.5, 121.7, 131.5, 131.7, 132.9, 135.6, 136.7, 
146.8 ppm; HRMS C12H11N: [M+Na
+
] calculated:
 
192.0789, found: 192.0794. 
 
(Z)-2-Benzylidene-5-(3-methoxy-phenyl)-pentanenitrile (25g): General Procedure B 
was employed with 23a (48 mg, 0.3 mmol) and 3-methoxy phenethyl magnesium 
bromide (1.8 ml, 0.90 mmol) to afford, after purification by radial chromatography (10% 
EtOAc in hexanes), 51.5 mg (62%) of 25g as an oil: IR (neat) 2936， 2209，1736 cm-1; 
1
H NMR (CDCl3, 400 MHz): δ 1.96 – 2.04 (m, 2H), 2.40 – 2.45 (m, 2H), 2.68 (t, J = 7.5 
Hz, 2H), 3.80 (s, 3H), 6.74 (s, 1H), 6.76 – 6.80 (m, 2H), 6.91 (s, 1H), 7.20 – 7.25 (m, 
2H), 7.35 – 7.43 (m, 3H), 7.71 – 7.42 (m, 2H); 13C NMR(CDCl3, 100 MHz): δ 29.5, 34.8, 
35.5, 55.1, 111.0, 111.3, 114.2, ,118.7, 120.8, 128.5, 128.8, 129.4, 129.9, 133.7, 142.8, 
143.7, 159.7 ppm; HRMS C12H11N: [M+Na
+
] calculated:
 
300.1365,  found: 300.1373. 
 
(Z)-2-(3,4-Dimethoxy-benzylidene)-4-methyl-pentanenitrile (25h): General Procedure 
C was employed with 23b (66 mg, 0.3 mmol) and isopropyl magnesium bromide (0.55 
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ml, 1.1 mmol) to afford, after purification by radial chromatography (15% EtOAc in 
hexanes), 44.0 mg (60%) of 25h as an oil: IR (neat) 2957， 2205cm-1; 1H NMR (CDCl3, 
400 MHz): δ 0.99 (d, J = 6.5 Hz, 6H), 1.96 – 2.06 (m, 1H), 2.23 – 2.25 (m, 1H), 3.92 (s, 
3H), 3.94 (s, 3H), 6.81 (s, 1H), 6.86 (d, J = 8.6 Hz, 1H), 7.19 (dd, J = 8.2 Hz, 2.0 Hz, 
1H), 7.54 (d, J = 2.0 Hz, 1H); 
13
C NMR (CDCl3, 100 MHz): δ 21.9, 27.6, 45.3, 55.9, 
107.6, 110.3, 110.8, 119.6, 123.1, 126.8, 144.0, 148.9, 150.5 ppm; HRMS C15H19NO2: 
[M+Na
+
] calculated:
 
284.1053, found: 284.1054. 
 
(2Z, 4E)-2-(3, 4-Dimethoxybenzylidene)-5-(trimethylsilyl)pent-4-enenitrile (25i): 
Neat  1, 2-dibromoethane (0.01 mL, 0.07 mmol) was added to a suspension of Mg (22.4 
mg, 0.89 mmol) in cold (0°C) THF (0.8 mL). Neat (E)-(2-(trimethylsilyl)vinyl) bromide 
(0.09 mL, 0.69 mmol) was added dropwise and after 1 h at 0 °C the THF solution of the 
resulting Grignard reagent was added to a -20 °C, THF solution (3 mL) of 2-((3, 4-
dimethoxyphenyl)(hydroxy)methyl) acrylonitrile 23b (50 mg, 0.23 mmol). After 3 h, the 
reaction mixture was poured into aqueous, saturated NH4Cl (2 mL). The aqueous phase 
was extracted with EtOAc (3 x 10 mL), the combined organic phase was washed with 
brine, dried (Na2SO4), concentrated and purified by radial chromatography (15% EtOAc 
in hexanes) to afford 36.8 mg (52%) of nitrile 25i as a light yellow oil: IR (neat) 2954, 
2206, 1600 cm
-1
,
1
H NMR (CDCl3, 500 MHz) : δ -0.01 (s, 9H), 3.16 (d, J = 6.6 Hz, 2H), 
3.92 (s, 3H), 3.94 (s, 3H), 5.88 (d, J = 18.0 Hz, 1H), 6.04 (dt, J = 18.0, 6.6 Hz, 1H), 6.84 
(s, 1H), 6.87 (d, J = 7.8 Hz, 1H), 7.19 (dd, J = 7.8, 1.8 Hz, 1H), 7.56 (d, J = 1.8 Hz, 1H); 
13
C NMR (CDCl3, 100 MHz) : δ -1.32, 42.7, 55.9, 106.2, 110.1, 110.7, 119.4, 123.3, 
126.6, 134.7, 140.3, 143.9, 148.8, 150.5 ppm; HRMS for C17H23NO2Si: [M+H
+
]
 
calculated 302.1577,
  
found 302.1563. 
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(2Z,4E)-2-(3,4-Dimethoxybenzylidene)-5-phenylpent-4-enenitrile (25j): A cold (0 °C) 
suspension of  Mg (22.4 mg, 0.89 mmol) in THF (0.8mL) was activated by adding 1,2-
dibromoethane (0.01 mL, 0.07 mmol) and after 5 min. β-bromostyrene (0.09 mL, 0.69 
mmol) was added dropwise. After 1 h at 0 °C the THF solution of the Grignard reagent 
was added to a -20 °C THF  solution (3 mL) of 2-((3,4-
dimethoxyphenyl)(hydroxy)methyl)acrylonitrile 23b (50 mg, 0.23 mmol).  After 3 h the 
reaction mixture was poured into an aqueous saturated NH4Cl solution (2 mL). The 
aqueous phase was extracted with EtOAc (3 x 10 mL), the combined organic phase was 
washed with brine, dried (Na2SO4), concentrated, and purified by radial chromatography 
(15% EtOAc in hexanes) to afford 44.5 mg (63%) of nitrile 25j as a light yellow oil: IR 
(neat) 2934, 2206, 1599 cm
-1
; 
1
H NMR (CDCl3, 500 MHz): δ 3.28 (d, J = 6.6 Hz, 2H), 
3.92 (s, 3H), 3.93 (s, 3H), 6.25 (td, J = 15.6, 7.2 Hz, 1H), 6.58 (d, J = 15.6 Hz, 1H), 6.88 
(d, J = 8.4 Hz, 1H), 6.92 (s, 1H),7.21 (d, J = 8.4 Hz, 1H), 7.26 (d, J = 7.8 Hz, 2H), 7.33 
(t, J = 7.8 Hz, 1H), 7.40 (d, J = 7.8 Hz, 2H), 7.53 (s, 1H); 
13
C NMR (CDCl3, 100 MHz): δ 
39.2, 56.0, 106.6, 110.4, 110.8, 119.4, 123.2, 124.4, 126.4, 126.6, 127.7, 128.6, 133.6, 
136.7,  143.8, 148.9, 150.7 ppm; HRMS for C20H19NO2 [M+Na
+
]
 
Calculated 328.1314, 
found 328.1321.   
 
 (Z)-2-(3,4-dimethoxybenzylidene)heptanenitrile (25k): General Procedure C was 
employed with 23b (40 mg, 0.18 mmol) and butylmagnesium chloride (0.27 mL, 0.55 
mmol) to afford, after purification by radial chromatography (15% EtOAc in hexanes), 
64.7 mg (83%) of 25k as an oil: IR (neat) 2930, 2204, 1599 cm
-1
; 
1
H NMR (CDCl3, 400 
MHz): δ 0.92 (t, J = 6.8 Hz, 3H), 1.30-1.40 (m, 4H), 1.60-1.70 (m, 2H), 2.37 (td, J = 8.0, 
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1.2 Hz, 2H), 6.84 (s, 1H), 6.87 (d, J = 8.4 Hz, 1H), 7.18 (dd, J = 8.4, 2.0 Hz, 1H), 7.53 (d, 
J = 2.4 Hz, 1H); 
13
C NMR (CDCl3, 100 MHz): δ 14.0, 22.4, 28.1, 30.9,  36.2, 55.9, 
108.7, 110.3, 110.8, 119.5, 123.0, 126.9, 143.1, 148.9, 150.4 ppm; HRMS for C16H21NO2 
[M+Na
+
]
 
calculated 282.1470,
  
found 282.1481. 
 
 
(Z)-2-(3,4-Difluorobenzylidene)heptanenitrile (25l): General Procedure C was 
employed with 23c (40 mg, 0.20 mmol) and butylmagnesium bromide (0.30 mL, 0.60 
mmol) to afford, after purification by radial chromatography (hexanes), 33 mg (68%) of 
25l as an oil: IR (neat) 2930, 2205, 1599 cm
-1
; 
1
H NMR (CDCl3, 500 MHz): δ 0.92 (t, J = 
5.5 Hz, 3H), 1.33-1.38 (m, 4H), 1.60-1.68 (m, 2H), 2.39 (t, J = 7.5 Hz, 2H), 6.83 (s, 1H), 
7.18 (q, J = 9.0 Hz, 1H), 7.42-7.46 (m, 1H), 7.56-7.62 (m, 1H); 
13
C NMR (CDCl3, 100 
MHz): δ 13.9, 22.3, 27.8, 30.8, 36.1, 113.0 (d, J = 3 Hz), 117.3 (d, J = 18 Hz), 117.7 (dd, 
J = 18, 1 Hz), 118.2, 125.2 (dd, J = 7, 4 Hz), 130.9 (dd, J = 6, 4 Hz), 140.7 (d, J = 2 Hz), 
150.3 (dd, J = 248, 12 Hz), 151.0 (dd, J = 252, 13 Hz) ppm; HRMS for C14H15NF2 
[M+Na
+
]
 
calculated:258.1071，found:258.1075. 
 
(2Z,4E)-5-Phenyl-2-(2-(trimethylsilyl)ethyl)penta-2,4-dienenitrile(25m) and (2E,4E)-
5-phenyl-2-(2-(trimethylsilyl)ethyl)penta-2,4-dienenitrile (25m’): General Procedure 
A was employed with 23d (40 mg, 0.22 mmol) and ((trimethylsilyl) methyl)magnesium 
chloride (0.65 mL, 0.65 mmol, 1 M in THF) to afford, after purification by radial 
chromatography (hexanes), 28.8 mg (52%) of 25m and 25m’ as a 6:1 mixture of oils. For 
25m: IR (neat) 2952, 2204 cm
-1
; 
1
H NMR (CDCl3, 500 MHz): δ 0.04 (s, 9H), 0.73-0.82 
(m, 2H), 2.26-2.32 (m, 2H), 6.74 (dd, J = 11.0, 1.0 Hz, 1H), 6.78 (d, J = 15.5 Hz, 1H), 
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7.15 (dd, J = 15.5, 11.0 Hz, 1H), 7.30 (t, J = 7.5 Hz, 1H), 7.36 (t, J = 7.5 Hz, 2H), 7.48 
(d, J = 7.0 Hz, 2H); 
13
C NMR (CDCl3, 100 MHz): δ -1.8, 15.6, 29.2, 116.4, 118.2, 124.7, 
127.2, 128.8, 129.1, 135.9, 138.5, 142.5 ppm. For 25m’: IR (neat) 2953, 2204 cm-1; 1H 
NMR (CDCl3, 500 MHz): δ 0.08 (s, 9H), 0.79-0.87 (m, 2H), 2.37-2.42 (m, 2H), 6.80 (d, J 
= 2.0 Hz, 1H), 6.83 (d, J = 4.4 Hz, 1H), 6.92-7.00 (m, 1H), 7.33 (t, J = 7.5 Hz, 1H), 7.38 
(t, J = 7.5 Hz, 2H), 7.46 (d, J = 7.0 Hz, 2H); 
13
C NMR (CDCl3, 125 MHz): δ -1.8, 16.0, 
23.7, 116.4, 121.7, 127.2, 128.9, 129.3, 139.7, 141.8 ppm; HRMS for C16H21NSi 
[M+Na
+
]
 
calculated: 278.1341,
 
found: 278.1345. 
 
(2E, 4Z)-2-ethyl-5-phenylpenta-2,4-dienenitrile (25n) and (2E, 4E)-2-ethyl-5-
phenylpenta-2,4-dienenitrile (25n’): General Procedure C was employed with 23d (40 
mg, 0.22 mmol) and methyl magnesium bromide (0.23 mL, 0.66 mmol) to afford, after 
purification by radial chromatography (hexanes), 21.7mg (54%) of 25n and 25n’ as a 4:1 
mixture of oils.  For 25n: IR (neat) 2205; 
1
H NMR (CDCl3, 400 MHz): δ 1.22 (t, J = 7.5 
Hz, 3H), 2.35 (q, J = 7.5 Hz, 2H), 6.75 (d, J = 11.1 Hz, 1H), 6.79 (d, J = 15 Hz, 1H), 7.15 
(dd, J = 11.1 Hz, 15 Hz, 1H), 7.29 – 7.49 (m, 5H); 13C NMR(CDCl3, 100 MHz): δ 12.9, 
22.5, 114.7, 120.6, 121.7, 127.2, 128.9, 129.3, 135.8, 140.0, 142.7 ppm. For 25n’: IR 
(neat) 2920, 2203cm
-1
; 
1
H NMR (CDCl3, 400 MHz): δ 1.23 (t, J = 7.5 Hz, 3H), 2.44 (q, J 
= 7.5 Hz, 2H), 6.81 – 6.87 (m, 2H), 6.99 (dd, J = 11.2 Hz, 15.3 Hz, 1H), 7.32 – 7.50 (m, 
5H); 
13
C NMR (CDCl3, 100 MHz): δ 12.8, 27.6, 114.8, 118.0, 124.6, 127.2, 128.8, 129.1, 
135.8, 138.7, 143.1 ppm. HRMS for C13H13N: [M+Na
+
]
 
calculated: 206.0946,
 
found: 
206.0940. 
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(2E, 4Z)-2-(3-Phenyl-allylidene)-heptanenitrile (25o) and (2E, 4E)-2-(3-Phenyl-
allylidene)-heptanenitrile (25o’): General Procedure C was employed with 23d (40 mg, 
0.22 mmol) and butylmagnesium bromide (0.35ml, 0.66mmol) to afford, after 
purification by radial chromatography (hexanes), 25.7 mg (50%) of 25o and 25o’ as a 6:1 
mixture of oils.  For 25o: IR (neat) 2930, 2208, 1451 cm
-1
; 
1
H NMR(CDCl3, 400 MHz): δ 
0.84 (t, J = 6.6 HZ, 3H), 1.22 – 1.32 (m, 4H), 1.48 – 1.56 (m, 2H), 2.24 (t, J = 7.6 HZ, 
2H), 6.66 (d, J = 11 HZ, 1H), 6.71 (d, J = 15.6 HZ, 1H), 7.08 (dd, J = 11HZ, 15.6 HZ, 
1H),  7.19 – 7.42 (m, 5H); 13C NMR (CDCl3, 400 MHz): δ 13.9, 22.3, 27.9, 30.9, 34.3, 
113.6, 118.1, 124.7, 127.2, 128.8, 129.1, 135.9, 138.7, 143.9 ppm; For 25o’: IR (neat) 
2926 , 2204, 1443 cm
-1
; 
1
H NMR(CDCl3, 400 MHz): δ 0.92 (t, J = 7.0 HZ, 3H), 1.35 – 
1.38 (m, 4H), 1.59 – 1.66 (m, 2H), 2.40 (t, J = 7.0 HZ, 2H), 6.81 – 7.02 (m, 3H),  7.130 – 
7.48 (m, 5H); 
13
C NMR(CDCl3, 100 MHz): δ 14.0, 22.4, 28.0, 29.0, 31.4, 113.5, 120.9, 
121,9, 127.2, 128.9, 129.3, 135.8, 139.9, 143.3 ppm. HRMS for C16H19N: [M+K
+
]
 
calculated: 264.1155,
  
found: 264.1188. 
 
(Z)-2-(3,4-dimethoxybenzylidene)pent-4-enenitrile (25p): General Procedure C was 
employed with 23b (1095.0mg, 5.0 mmol) and vinyl nmagnesium bromide (21.4ml, 
15.0mmol) to afford, after purification by radial chromatography (15% EtOAc in 
hexanes), 756.8 mg (62%) of 25p as an oil: IR (film) 2938, 2200,1512 cm
-1
; 
1
H NMR 
(CDCl3, 400 MHz): δ 3.11 – 3.13 (m, 2H), 3.92 (s, 3H), 3.93 (s, 3H), 5.22 – 5.28 (m, 
2H), 5.85 – 5.92 (m, 1H), 6.87 (d, J = 8.6 Hz, 1H), 6.87 (s, 1H), 7.20 (dd, J = 8.6 Hz, 2 
Hz), 7.54 (d, J = 2 Hz, 1H);
 13
C NMR (CDCl3, 100 MHz): δ 39.9, 55.9, 106.4, 110.3, 
110.8, 118.6, 119.3, 123.2, 126.6, 133.1, 143.8, 148.9, 150.6 ppm; HRMS C14H15NO2: 
[M+Na
+
] calculated:
 
252.1001, found: 252.0974. 
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(2Z, 4E)-2-(3,4-Dimethoxybenzylidene)-5-(3,4-dimethoxyphenyl)pent-4-enenitrile 
(27): A DMF solution (8 mL) of (3,4-dimethoxyphenyl) boronic acid (124.7 mg, 0.66 
mmol), palladium acetate (9.8 mg, 0.04 mmol), silver carbonate (87.3 mg, 0.87 mmol) 
and (Z)-2-(3,4-dimethoxybenzylidene)pent-4-enenitrile (100.0 mg, 0.44 mmol) was 
heated at 50 °C. After 12 h, the mixture was cooled and then the reaction mixture was 
poured into water (2 mL). The aqueous phase was extracted with EtOAc (3 x 10 mL), the 
combined organic phase was washed with brine, dried (Na2SO4), concentrated, and 
purified by radial chromatography (30% EtOAc in hexanes) to afford 81.5 mg (51%) of 
nitrile 27 as a yellow solid (mp: 88-89 °C): IR (neat) 2931, 2206 cm
-1
; 
1
H NMR (CDCl3, 
500 MHz): δ 3.26 (d, J = 7.2 Hz, 2H), 3.89 (s, 3H), 3.91 (s, 3H), 3.92 (s, 3H), 3.93 (s, 
3H), 6.11 (dt, J = 16.0, 6.8 Hz, 1H), 6.51 (d, J = 16.0 Hz, 1H), 6.88 (d, J = 8.4 Hz, 1H), 
6.92 (d, J = 8.4 Hz, 1H), 6.93 (d, J = 2.0 Hz, 1H), 6.93 (s,  1H), 6.95 (s, 1H), 7.21 (dd, J 
= 8.4, 2.0 Hz, 1H), 7.54 (d, J = 2.0 Hz, 1H); 
13
C NMR (CDCl3, 100 MHz) : δ   39.2, 55.9 
(2), 56.0, 106.8, 108.8, 110.4, 110.8, 111.1, 119.5, 119.53, 122.5, 123.2, 126.6, 129.8, 
133.2, 143.7, 148.90, 148.95, 149.03, 150.7 ppm; HRMS for C22H23NO4 [M+Na
+
]
 
calculated: 388.1525,
  
found: 388.1517. 
 (2Z, 4E)-2-(3, 4-Dimethoxybenzylidene)-5-(3,4-dimethoxyphenyl)pent-4-enamide 
(28): Solid Parkins catalyst [bis(dimethylphosphinous acid-kP)dimethylphosphinyl-kP-
hydridoplatinum(II)] (0.5 mg, 0.0075 mmol) was added to an ethanol/water solution (1:1, 
20 mL)  of (2Z, 4E)-2-(3,4-dimethoxybenzylidene)-5-(3,4-dimethoxyphenyl)pent-4-
enenitrile (54.8 mg, 0.15 mmol) and then the reaction mixture was heated to reflux. After 
15 h, the solution was cooled, the solvent was evaporated, and then the residue was 
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purified by radial chromatography (70% EtOAc in hexanes) to afford 50.0 mg (87%) of 
the amide 28 as a white solid (mp: 108-109 °C): IR (solid) 3416, 3338, 2935, 1672, 1518 
cm
-1
; 
1
H NMR (CDCl3, 500 MHz): δ  3.31 (d, J = 7.2 Hz, 2H), 3.86 (s, 3H), 3.88 (s, 6H), 
3.91 (s, 3H), 5.42 (s, 2H), 6.14 (dt, J = 16.0, 7.2 Hz, 1H), 6.47 (d, J = 16.0 Hz, 1H), 6.57 
(s, 1H), 6.82 (dd, J = 8.4, 2.0 Hz, 2H), 6.90-6.97 (m, 4H); 
13
C NMR (CDCl3, 100 MHz) : 
δ  39.8, 55.9, 56.0, 108.7, 111.0, 111.1, 111.3, 119.3, 121.3, 124.3, 128.3, 130.2, 130.3, 
132.3, 135.3, 148.7, 148.9, 149.0, 172.1 ppm; HRMS for C22H25NO5 [M+Na
+
]
 
calculated: 
406.1631
  
found: 406.1619. 
 
tert-Butyl(2Z,4E)-2-(3,4-dimethoxybenzylidene)-5-(3,4-dimethoxyphenyl)pent-4- 
enoylcarbamate (29): Solid di-tert-butyldicarbonate (43.4 mg, 0.20 mmol) and 4-
dimethyaminopyridine (1.2 mg,0.01 mmol) were added to a rt, CH2Cl2 solution (5mL) of 
(2Z, 4E)-2-(3,4-dimethoxybenzylidene)-5-(3,4-dimethoxyphenyl)pent-4-enamide (40 mg, 
0.10 mmol). After 20 h, the reaction mixture was poured into dichloromethane (10 mL), 
the phases were separated, the organic phase was combined and was then washed 
sequentially with 1M HCl (10 mL) and water (10 mL). The solvent was evaporated and 
the residue was then purified by radial chromatography (30% EtOAc in hexanes) to 
afford 35.3 mg (73 %) of imide 29 as a light yellow oil: IR (neat) 2979, 1777, 1601 cm
-1
,
 
1
H NMR (CDCl3, 500 MHz):  δ 1.43 (s, 9H), 3.31 (d, J = 7.2 Hz, 2H), 3.87 (s, 3H), 3.88 
(s, 3H), 3.89 (s, 3H), 3.90 (s, 3H), 6.22 (dt, J = 11.6, 7.2 Hz, 1H),  6.51 (d, J = 11.6 Hz, 
1H), 6.51 (s, 1H), 6.80-7.02  (m, 7H);  
13
C NMR (CDCl3, 100 MHz): δ 27.8, 38.4, 55.8, 
55.9, 84.6, 108.7, 110.8, 111.0, 111.1, 119.4, 124.0, 128.1, 130.5, 130.7, 132.7, 133.5, 
 39 
148.6, 148.7, 149.0, 149.3, 170.7 ppm; HRMS for C27H33NO7 [M+H
+
]
 
calculated: 
484.2236,
  
found: 484.2325. 
 
(2Z, 4E)-2-(3,4-Dimethoxybenzylidene)-5-(3,4-dimethoxyphenyl)pent-4-en-1-ol (30): 
A THF solution (0.13 mL) of lithium triethylborohydride (0.13 mmol, 1 M ) was added to 
a rt, THF solution (5 mL) of tert-butyl((2Z,4E)-2-(3,4-dimethoxybenzylidene)-5-(3,4-
dimethoxyphenyl)pent-4-enoyl)carbamate (30 mg, 0.06 mmol). After 2 h, an aqueous 
solution (10 mL) of 30% H2O2 was added. After 30 min, the aqueous phase was extracted 
with EtOAc (3 x 10 mL), the combined organic phase was washed with brine, dried 
(Na2SO4), concentrated, and purified by radial chromatography (30% EtOAc in hexanes) 
to afford 16.0 mg (72%) of alcohol 30 as a light yellow oil: IR (neat) 3520, 2935, 1598 
cm
-1
;
 1
H NMR (CDCl3, 400 MHz): δ 1.59 (broad s, 1H), 3.20 (d, J = 7.0 Hz, 2H), 3.88 (s, 
6H), 3.89 (s, 3H), 3.91 (s, 3H), 4.34 (s, 2H), 6.20 (dt, J = 15.8 Hz, 7.2 Hz, 1H), 6.47 (d, J 
= 15.8 Hz, 2H), 6.81–6.96 (m, 6H);  13C NMR (CDCl3, 100 MHz): δ 39.5, 55.8, 55.9, 
55.9, 61.3, 108.6, 110.9, 111.1, 112.0, 119.1, 121.2, 126.0, 129.4, 129.8, 130.4, 131.7, 
138.5, 148.1, 148.5, 148.6, 149.0 ppm; HRMS for C22H26O5 [M+H
+
]
 
calculated: 
393.1678,
  
found: 393.1696. 
 
(2Z,4Z)-2-(3,4-Dimethoxybenzylidene)-5-iodopent-4-enenitrile (31): Solid N-iodo 
succinimide (146.3 mg, 0.65 mmol) was added to a 0 °C 1,1,1,3,3,3-
hexafluoroisopropanol and dichloromethane (1:1) solution (1.6 mL) of (2Z,4E)-2-(3,4-
dimethoxybenzylidene)-5-(trimethylsilyl)pent-4-enenitrile (130 mg, 0.43 mmol). After 10 
min, the reaction mixture was poured into an aqueous, saturated NH4Cl solution (2mL). 
The aqueous phase was extracted with EtOAc (3 x10 mL), the combined organic phase 
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was washed with brine, dried (Na2SO4), concentrated, and purified by radial 
chromatography (15% EtOAc in hexanes) to afford 125 mg (82%) of nitrile 31 as a light 
yellow oil. IR (neat) 2934, 2206, 1597 cm
-1
; 
 1
H NMR (CDCl3, 500 MHz): δ 3.26 (d, J = 
6.6 Hz, 2H), 3.93 (s, 3H), 3.94 (s, 3H), 6.39 (dt, J =7.6, 7.6 Hz, 1H), 6.57 (dt, J = 7.6 Hz, 
1.4 Hz, 1H), 6.89 (d, J = 8.4 Hz, 1H), 6.95 (s, 1H), 7.21 (dd, J = 8.4, 2.4 Hz, 1H), 7.52 (d, 
J = 2.4 Hz, 1H); 
13
C NMR (CDCl3, 100 MHz) : δ 40.8, 55.9 (2), 86.6, 104.0, 110.2, 
110.7, 119.2, 123.4, 126.3, 135.6, 144.3, 148.8, 150.7 ppm; HRMS for C14H14NO2I 
[M+Na
+
]
 
calculated: 377.9967,
  
found: 377.9944. 
 
(2Z, 4Z)-2-(3,4-Dimethoxybenzylidene)-5-(3,4-dimethoxyphenyl)pent-4-enenitrile 
(32):  Solid (3,4-dimethoxyphenyl) boronic acid (87.8 mg, 0.46 mmol), palladium acetate 
(14.0 mg,0.06 mmol) and triphenyl phosphine (32.5 mg, 0.12 mmol) were added to a rt, 
THF solution (8 mL) of (2Z,4E)-2-(3,4-dimethoxybenzylidene)-5-iodopent-4-enenitrile 
(100.0 mg, 0.31 mmol). After 12 h, the reaction mixture was poured into water (2 mL). 
The aqueous phase was extracted with EtOAc (3 x 10 mL), the combined organic phase 
was washed with brine, dried (Na2SO4), concentrated, and purified by radial 
chromatography (30% EtOAc in hexanes) to afford 88.3 mg (78%) of nitrile 32 as a light 
yellow oil: IR (neat) 2931, 2206 cm
-1
; 
1
H NMR (CDCl3, 500 MHz): δ 3.39 (d, J = 7.8 Hz, 
2H), 3.89 (s, 3H), 3.90 (s, 3H), 3.92 (s, 3H), 3.93 (s, 3H), 5.72 (dt, J = 11.4, 7.2 Hz, 1H), 
6.67 (d, J = 11.4 Hz, 1H), 6.83 (s, 1H),  6.85-6.89 (m, 3H), 6.91 (s, 1H), 7.19 (dd, J = 8.4, 
1.8 Hz, 1H), 7.53 (d, J = 1.8 Hz, 1H); 
13
C NMR (CDCl3, 100 MHz): δ 34.7, 55.9 (2), 
106.8, 110.3, 110.8, 111.0, 111.9, 119.5, 121.1, 123.2, 124.9, 126.6, 129.3, 132.5, 143.6, 
148.3, 148.7, 149.0, 150.7 ppm; HRMS for C22H23NO4 [M+Na
+
]
 
calculated:388.1525,
  
found:388.1512. 
 41 
 
(2Z, 4Z)-2-(3, 4-Dimethoxybenzylidene)-5-(3, 4-dimethoxyphenyl)pent-4-enamide 
(33): Solid Parkins catalyst [bis(dimethylphosphinous acid-kP)dimethylphosphinyl-kP-
hydridoplatinum(II)] (0.6 mg, 0.01 mmol) was added to an ethanol/water solution (1:1, 
20 mL) of (2Z, 4Z)-2-(3,4-dimethoxybenzylidene)-5-(3,4-dimethoxyphenyl)pent-4-
enenitrile (80 mg, 0.22 mmol) and then the reaction was heated to reflux. After 15 h, the 
solvent was evaporated and the residue was purified by radial chromatography (70% 
EtOAc in hexanes) to afford 95.1 mg (92%) of amide 33 as a white solid (mp: 101-102 
°C): IR (solid) 3411，3339，2934, 2836, 1677, 1601 cm-1; 1H NMR (CDCl3, 400 MHz): 
δ 3.48 (d, J = 7.6 Hz, 2H), 3.88 (s, 3H), 3.90 (s, 3H), 3.91 (s, 3H), 3.92 (s, 3H), 5.43 (s, 
2H), 5.75 (dt, J = 11.6, 7.6 Hz, 1H), 6.59 (s, 1H), 6.61 (d, J = 11.6 Hz, 1H), 6.80-7.00 (m, 
6H); 
13
C NMR (CDCl3, 100 MHz): δ 34.1, 55.9 (2), 111.0, 111.3, 111.9, 121.2 (2), 126.3, 
128.3, 129.8 (2), 131.4, 135.2, 148.1, 148.7, 148.8, 172.3 ppm; HRMS for C22H25NO5 
[M+Na
+
]
 
calculated: 406.1631,
 
found: 406.1618. 
 
tert-Butyl((2Z,4Z)-2-(3,4-dimethoxybenzylidene)-5-(3,4-dimethoxyphenyl)pent-4-
enoyl)carbamate (34): Solid di-tert-butyl dicarbonate (136.8 mg, 0.63 mmol) and 4-
dimethyamino pyridine (2.9 mg, 0.02 mmol) were added to a CH2Cl2, rt, solution (5 mL) 
of (2Z, 4Z)-2-(3,4-dimethoxybenzylidene)-5-(3,4-dimethoxyphenyl)pent-4-enamide (90 
mg, 0.24 mmol). After 20 h the reaction mixture was poured into dichloromethane (10 
mL) and washed sequentially with 1M HCl (10 mL) and water (10 mL). The solvent was 
evaporated and the residue was then purified by radial chromatography (30% EtOAc in 
hexanes) to afford 88.3 mg (76 %) of imide 34 as a light yellow oil: IR (neat) 3296, 2930, 
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1766, 1686 cm
-1
;
 1
H NMR (CDCl3, 500 MHz): δ 1.38 (s, 9H), 3.45 (d, J = 7.8 Hz, 2H), 
3.85 (s, 3H), 3.88 (s, 3H), 3.89 (s, 3H), 3.91 (s, 3H), 5.73 (dt, J = 11.4, 7.2 Hz, 1H), 6.61 
(d, J = 6.0 Hz, 1H), 6.62 (d, J = 6.0 Hz, 1H), 6.80-6.92  (m, 7H); 
13
C NMR (CDCl3, 100 
MHz): δ 27.8, 33.6, 55.8, 55.9 (2), 82.7, 110.7, 110.8, 110.9, 111.6, 121.2, 125.6, 127.8, 
129.6, 131.8, 134.6, 148.1, 148.6, 148.8, 149.0, 149.1 ppm;  HRMS for C27H33NO7 
[M+Na
+
]
 
calculated: 506.2155,
  
found: 506.2155. 
 
(1Z, 4Z)-1,5-Bis(3,4-dimethoxyphenyl)penta-1,4-dien-2-ol (35): A THF solution (0.34 
mL) of lithium triethylborohydride (0.34 mmol, 1 M) was added to a rt, THF solution (5 
mL) of tert-butyl((2Z,3E)-2-(3,4-dimethoxybenzylidene)-5-(3,4-dimethoxyphenyl)pent-
4-enoyl)carbamate (80 mg, 0.17 mmol). After 2 h, an aqueous 30% solution (10 mL) of 
H2O2 was added. After 30 min, the aqueous phase was extracted with EtOAc (3 x 10 
mL), the combined organic phase was washed with brine, dried (Na2SO4), concentrated 
and purified by radial chromatography (30% EtOAc in hexanes) to afford 43.4 mg (69%) 
of alcohol 35 as a light yellow oil: IR (neat) 3517, 2925, 1514 cm
-1
;
 1
H NMR (CDCl3, 
400 MHz): δ  1.28 (s, 1H), 3.36 (d, J = 7.0 Hz, 2H), 3.88 (s, 6H), 3.89 (s, 3H), 3.91 (s, 
3H), 4.35 (s, 2H), 5.82 (dt, J = 11.6 Hz, 7.6 Hz, 1H), 6.51(s, 1H), 6.66 (d, J = 11.6 Hz, 
1H), 6.81–6.96 (m, 6H);  13C NMR (CDCl3, 400 MHz): δ 34.7, 55.9 (3), 77.2, 110.9, 
111.9, 112.0, 121.1, 121.2, 128.0, 129.0, 130.0, 131.0, 138.7, 148.0 ppm; HRMS for 
C22H26O5 [M+Na
+
]
 
calculated: 393.1678,
  
found: 393.1691.   
 
Rearrangement to allylic halides and sulfide 
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(1-chloropentyl) benzene (47): Butylmagnesium bromide (0.62ml, 1.24mmol) was 
added dropwise to a 0 °C, THF (0.8ml) solution of benzaldehyde(0.095ml, 0.94mmol) 
and the solution was then allowed to react in 0°C for 1h. Dry niobium chloride (634.5mg, 
2.35mmol) and dioxane (8ml) was added, and then the solution was allowed to warm to 
room temperature. After 1h, the reaction mixture was poured into HCl (2M),and the 
phases were separated. The aqueous phase was extracted with EtOAc, and then the 
combined organic phase was washed with brine, dried (NaSO4), and concentrated to 
provide an oil which was purified by radical chromatography (hexanes) afforded 132.2 
mg (77%) of chloride 47 as an oil: IR (neat) 1713, 1494, 1454 cm
-1
; 
1
H NMR (CDCl3, 
500 MHz) δ 0.89 (t, J= 7.2Hz, 3H), 1.31-1.36 (m, 4H), 2.04-2.14 (m, 2H), 4.84 (dd, J= 
8.0Hz, J= 7.0Hz, 1H), 7.29-7.38 (m, 5H); 
13
C NMR (CDCl3, 100MHz) δ 13.9, 22.1, 
29.2, 39.7, 63.9, 126.9, 128.2, 128.6, 142.0 ppm. 
 
(1-chloropentyl) benzene (47): Butyl lithium (0.49ml, 1.13mmol) was added dropwise 
to a -78°C, THF (0.8ML) solution of benzaldehyde (0.095ml, 0.94mmol) and the solution 
were then allowed to react in 0°C for 1h. Dry niobium chloride (634.5mg, 2.35mmol) and 
dioxane (8ml) was added, and then the solution was allowed to warm to room 
temperature. After 1h, the reaction mixture was poured into HCl (2M), and the phases 
were separated. The aqueous phase was extracted with EtOAc, and then the combined 
organic phase was washed with brine, dried (NaSO4), and concentrated to provide an oil 
which was purified by radical chromatography (hexanes) afforded 89.3 mg (52%) of 
chloride 47 as an oil: IR (neat) 1713, 1494, 1454 cm
-1
; 
1
H NMR (CDCl3, 500 MHz) δ 
0.89 (t, J= 7.2Hz, 3H), 1.31-1.36 (m, 4H), 2.04-2.14 (m, 2H), 4.84 (dd, J= 8.0Hz, J= 
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7.0Hz, 1H), 7.29-7.38 ( m, 5H); 
13
C NMR (CDCl3, 100 MHz) δ 13.9, 22.1, 29.2, 39.7, 
63.9, 126.9, 128.2, 128.6, 142.0 ppm. 
 
 (1,5-dichloropentyl)benzene (49): (4-chlorobutyl) bromide (0.145ml, 1.23mmol) was 
added dropwise to a 0°C, THF (0.8ml) suspension of Mg (45.2mg, 1.89mmol), activated 
by addition of 1, 2-dibromoethane (0.01ml, 0.2mmol) and allowed to react at 0 for 1h. 
Then benzaldehyde (0.095ml, 0.94mmol) was added to the mixture and the solution was 
then allowed to react in 0°C for 1h. Dry niobium chloride (634.5mg, 2.35mmol) and 
dioxane (8ml) was added, and then the solution was allowed to warm to room 
temperature. After 1h, the reaction mixture was poured into HCl (2M), and the phases 
were separated. The aqueous phase was extracted with EtOAc, and then the combined 
organic phase was washed with brine, dried (NaSO4), and concentrated to provide an oil 
which was purified by radical chromatography (hexanes) afforded 146.9 mg (72%) of 
dichloride 49 as an oil: IR (neat) 2944, 1454 cm
-1
; 
1
H NMR (CDCl3, 400 MHz) δ 1.56 
(m, 1H), 1.77-1.83(m, 1H), 2.05-2.17 (m, 2H), 3.52 (t, J= 6.4Hz, 2H), 4.85 (dd, J= 
8.0Hz,  J= 6.4Hz, 1H), 7.32-7.39 (m, 5H); 
13
C NMR (CDCl3, 100 MHz) δ 24.5, 32.0, 
39.3, 44.6, 63.4, 126.9, 128.3, 128.7, 141.6 ppm. 
 
 (E)-(3-(3-methoxyphenyl)allyl)(phenyl)sulfane (51): Vinyl magnesium bromide 
(0.7M, 1.2mmol) was added dropwise to a 0°C, THF solution (0.5ml) of 3-
methoxybenzaldehyde (136.15mg, 1.0 mmol). After 1 h, the solid niobium chloride 
(325.08mg, 1.2mmol) and dioxane (5ml) was added at 0°C. After 1h, the reaction 
 45 
mixture was poured into HCl (2M), and the phases were separated. The aqueous phase 
was extracted with EtOAc, and then the combined organic phase was washed with brine, 
dried (NaSO4), and concentrated to provide an oil. A THF solution (0.2M) of the crude 
allylic chloride was added to a 10°C, THF suspension of NaH and thiophenol. The 
reaction mixture was allowed to warm to r.t. Over 16h, the reaction mixture was poured 
into an aq NaOH solution (2%) and then extracted with EtOAC, and then the combined 
organic phase was washed with brine, dried (NaSO4), and concentrated to provide an oil 
which can be purified by radical chromatography (hexanes)  to provide the pure sulfide 
146.2 mg (57%): IR (neat) 3517, 2925, 1514 cm
-1
; 
1
H NMR (CDCl3, 500 MHz) δ 3.69 
(d, J=1.0Hz, 1H), 3.71 (d, J=1.0Hz, 1H), 3.79 (s, 3H), 6.25 (dt, J=15.5Hz, J=7.0Hz, 1H), 
6.38 (d, J=15.5Hz, 1H), 6.84 (ddd, J=8.0Hz, J=2.0Hz, J=0.5Hz, 1H), 6.89 (t, J=2.0Hz, 
1H), 6.91 (d, J=8.0Hz, 1H), 7.18-7.39 (m, 6H); 
13
C NMR (CDCl3, 100 MHz) δ 37.1, 
55.3, 111.7, 113.2, 119.1, 125.5, 126.5, 128.9, 129.5, 130.3, 132.7, 138.2, 159.8 ppm. 
HRMS for C16H16OS [M+Na
+
]
 
calculated: 257.0995,
 
found: 257.1021;   
 
Cinnamyl (phenyl) sulfane (53): Solid LiBH4 (2mg, 0.09mmol) was added to a rt, THF 
solution (1.0ml) of 1-phenylprop-2-en-1-one (24mg, 0.18 mmol). After 1h the mixture 
was cooled to 0°C, and then dioxane (5.0ml) and solid NbCl5 (56.9mg, 0.22mmol) were 
added. The cooling bath was removed and the reaction was allowed to warm to rt. After 
1h aqueous HCl (1M, 1ml) was added, the aqueous phase was extracted with EtOAc, the 
combined organic extracts were sequentially washed with water and brine, and then dried 
(Na2SO4) and concentrated to afford 17.8 mg of (E)-(3-chloroprop-1-enyl) benzene as an 
oil spectally identical to the material  previously identified
111
. A portion of crude (E)-(3-
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chloroprop-1-enyl) benzene (5.8mg, 0.04mmol) was dissolved in THF (2ml) and then 
added to a rt, THF (3ml) solution containing NaH (3.8mg, 0.1mmol) and benzenethiol 
(0.01ml, 0.1mmol). After 16h water was added, the aqueous phase was extracted with 
EtOAc, and the combined organic extracts were washed with brine, dried (Na2SO4) and 
concentrated. Purification by radical chromatography (hexanes) provided 4.7 mg (54%) 
of pure cinnamyl (phenyl) sulfane 53 as an oil. 
 
General procedure of Propargyllic alcohol:  
A THF solution of ethynyl magnesium chloride (0.6M, 3.6 mmol) was added dropwise to 
a 0 °C THF solution of aldehyde (3.0mmol). After 2 h, saturated, aqueous, NH4Cl (10ml) 
was added, the aqueous phase was extracted with EtOAc, and the combined organic 
extracts were washed with brine, dried (NaSO4), and concentrated. Purification by radical 
chromatography afforded propargillic alcohol as an oil.  
 
1-phenylprop-2-yn-1-ol (54a): Following the general procedure with a THF solution of 
ethynyl magnesium chloride (6.0 ml, 3.6 mmol), benzaldehyde  (318.3 mg, 3.0 mmol) 
and purification by radical chromatography (10% EtOAc in hexanes) afforded 297.1 mg 
(75%) of 1-phenylprop-2-yn-1-ol as an oil: 
1
H NMR (CDCl3, 400 MHz) δ 2.61 (d, J= 
2.4Hz, 1H), 3.00 (s, 1H), 5.37 (s, 1H), 7.29-7.50 (m, 5H); 
13
C NMR (CDCl3, 100 MHz) δ 
64.3, 75.0, 84.7, 127.0, 129.0, 129.0, 140.1 ppm. 
 
non-1-yn-3-ol (54b): Following the general procedure with a THF solution of ethynyl 
magnesium chloride (6.0 ml, 3.6 mmol), heptanal (342.6 mg, 3.0 mmol) and purification 
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by radical chromatography (10% EtOAc in hexanes) afforded 239.6 mg (57%) of non-1-
yn-3-ol as an oil: 
1
H NMR (CDCl3, 400 MHz) δ 0.87 (t, J= 7.2Hz, 3H), 1.21-1.40 (m, 
6H), 1.42-1.46 (m, 2H), 1.66-1.73 (m, 2H), 2.46 (d, J= 2.0 Hz, 1H), 4.35 (td, J= 6.4Hz,  
J= 2.0Hz, 1H); 
13
C NMR (CDCl3, 100 MHz) δ 14.1, 22.6, 25.0, 28.9, 31.7, 37.6, 62.2, 
72.7, 85.1 ppm. 
 
5-phenylpent-1-yn-3-ol (54c): Following the general procedure with a THF solution of 
ethynyl magnesium chloride (6.0 ml, 3.6 mmol), 3-phenylpropanal (402.5 mg, 3.0 mmol) 
and purification by radical chromatography (10% EtOAc in hexanes) afforded 381 mg 
(79%) of 5-phenylpent-1-yn-3-ol as an oil: 
1
H NMR (CDCl3, 500 MHz) δ 1.84 (d, J=5.5 
Hz, 1H), 2.01-2.07 (m, 2H), 2.50 (d, J=2.0 Hz, 1H), 2.81 (t, J=7.5 Hz, 2H), 4.37 (q, J=6.5 
Hz ,1H), 7.20-7.30 (m, 5H); 
13
C NMR (CDCl3, 100 MHz) δ 31.3, 39.1, 61.6, 73.4, 84.6, 
126.1, 128.5, 141.1 ppm.  
 
2-cyclohexylbut-3-yn-2-ol (54d): Following the general procedure with a THF solution 
of ethynyl magnesium chloride (6.0 ml, 3.6 mmol), 1-cyclohexylethanone (378.3 mg, 3.0 
mmol) and purification by radical chromatography (10% EtOAc in hexanes) afforded 
218.3 mg (48%) of 2-cyclohexylbut-3-yn-2-ol as an oil: 
1
H NMR (CDCl3, 400 MHz) 
δ1.14-1.24 (m, 6H), 1.45 (s, 3H), 1.79-1.80 (m, 1H), 1.82 (m, 3H), 1.93 (m, 2H) 2.42 (s, 
1H); 
13
C NMR (CDCl3, 100 MHz) δ 26.2, 26.3, 27.2, 27.3, 27.7, 48.5, 71.0, 71.9, 87.2 
ppm. 
 
General procedure of rearrangement to allenyl bromide: A dioxane solution of the 
propargyllic alcohol (0.58 mmol) was added to a dioxane solution of potassium hydride 
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(0.70 mmol). After 10 min, the solid niobium bromide (0.70mmol) was added.  After 2 h, 
the reaction mixture was poured into HCl (2M), and the phases were separated. The 
aqueous phase was extracted with EtOAc, and then the combined organic phase was 
washed with brine, dried (NaSO4), and concentrated to provide an oil which was purified 
by radical chromatography. 
 
(3-bromopropa-1,2-dienyl)benzene(56a): Following  the general procedure with a 
dioxane solution(3ml) of 1-phenylprop-2-yn-1-ol (20.0 mg, 0.15 mmol), potassium 
hydride (7.2 mg, 0.18 mmol), niobium bromide (88.6 mg, 0.18 mmol)  and purification 
by radical chromatography (hexanes) afforded 15.4 mg (53%) of (3-bromopropa-1,2-
dienyl)benzene as an oil: IR (neat) 1953, 1496, 1453 cm
-1
; 
1
H NMR (CDCl3, 400 MHz) δ 
6.32 (d, J=5.6 Hz, 1 H), 6.36 (d, J=5.6 Hz, 1H), 7.26-7.36 (m, 5H); 
13
C NMR (CDCl3, 
100 MHz) δ 74.8, 102.6,127.9, 128.6, 128.8, 131.7, 203.0 ppm. 
 
1-bromonona-1,2-diene (56b): Following the general procedure with a dioxane 
solution(10ml) of non-1-yn-3-ol (220.0 mg, 1.57 mmol), potassium hydride (75.2mg, 
1.88 mmol), niobium bromide (925.0 mg, 1.88 mmol) and purification by radical 
chromatography (hexanes) afforded 197.7 mg  (62%) of 1-bromonona-1, 2-diene as an 
oil: IR (neat) 1978, 1621, 1451 cm
-1
; 
1
H NMR (CDCl3, 400 MHz) δ 0.89 (t, J=6.8Hz, 
3H), 1.26-1.45 (m, 9H), 2.15 (qd, J=6.4 Hz, J=2.4 Hz, 2H), 5.39 (q, J=6.4 Hz, 1H), 5.93 ( 
dtd, J=5.2 Hz, J=2.4 Hz, J=0.4 Hz, 1H); 
13
C NMR (CDCl3, 400 MHz) δ 14.1, 22.6, 28.3, 
28.7, 29.7, 31.6, 72.1, 101.1, 202.1 ppm. 
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(5-bromopenta-3, 4-diene) benzene (56c): Following  the general procedure with a 
dioxane solution(6ml) of 5-phenylpent-1-yn-3-ol 54a (93 mg, 0.58 mmol), potassium 
hydride (27.8 mg, 0.70 mmol), niobium bromide (343.2 mg, 0.70 mmol), and purification 
by radical chromatography (hexanes) afforded 83.3 mg (65%) of (5-bromopenta-3, 4-
diene) benzene as an oil: IR (neat) 1980, 1451 cm
-1
; 
1
H NMR (CDCl3, 400 MHz) δ 2.47-
2.49 (m, 2H), 2.78 (t, J=7.0Hz, 2H), 5.43 (q, J=6.5 Hz, J=5.5 Hz, 1H), 5.95 (dt, J=5.5 
Hz, J=2.0 Hz, 1H), 7.19-7.31 (m, 5H); 
13
C NMR (CDCl3, 100 MHz) δ 29.9, 34.6, 72.7, 
100.1, 126.1, 128.4, 140.9, 202.2 ppm. 
 
(4-bromobuta-2,3-dien-2-yl)cyclohexane(56d): Following  the general procedure with a 
dioxane solution(3ml) of 2-cyclohexylbut-3-yn-2-ol (37.0 mg, 0.24 mmol), potassium 
hydride (11.7 mg, 0.29 mmol), niobium bromide (141.7 mg, 0.29 mmol)   and 
purification by radical chromatography (10% EtOAc in hexanes) afforded 29.3 mg (57%) 
of (4-bromobuta-2,3-dien-2-yl)cyclohexane as an oil: IR (neat) 1986, 1716 cm
-1
; 
1
H 
NMR (CDCl3, 400 MHz) δ 0.96-1.01 (m, 2H), 1.12 (m, 1H), 1.20-1.23 (m, 2H), 1.26 (S, 
3H), 1.31-1.37 (m, 2H),1.65 (d, J= 7.0Hz, 1H), 1.78 (d, J=10.0 Hz, 3H) 6.26 (d, J=1.5 
Hz, ,1H); 
13C NMR (CDCl3, 100 MHz) δ 25.4, 26.3, 26.4, 26.5, 27.0, 27.4, 48.1, 105.0, 
143.38, 192.7 ppm. 
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